Badanie CDPATH™ pomocne w zarządzaniu i leczeniu choroby Leśniowskiego-Crohna (COMPASS-CD)
Badanie fazy 4 oceniające rzeczywiste wykorzystanie CDPATH™, narzędzia do prognozowania ryzyka choroby Leśniowskiego-Crohna
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.
The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85032
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Loma Linda, California, Stany Zjednoczone, 92357
- VA Loma Linda Healthcare System
-
Murrieta, California, Stany Zjednoczone, 92563
- United Medical Doctors
-
Newport Beach, California, Stany Zjednoczone, 92663
- University of Southern California Medical Center
-
Orange, California, Stany Zjednoczone, 92868
- University of California at Irvine Medical Center
-
Orange, California, Stany Zjednoczone, 92868
- Clinnova Research Solutions
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80014
- Kaiser Permanate of Colorado
-
-
Connecticut
-
Hamden, Connecticut, Stany Zjednoczone, 06518
- Medical Research Center of Connecticut, LLC
-
-
Florida
-
Clearwater, Florida, Stany Zjednoczone, 33762
- West Central Gastroenterology d/b/a Gastro Florida
-
Pensacola, Florida, Stany Zjednoczone, 32503
- Gastroenterology Associates of Pensacola, PA
-
-
Idaho
-
Idaho Falls, Idaho, Stany Zjednoczone, 83404
- Grand Teton Research Group, PLL
-
-
Illinois
-
Arlington Heights, Illinois, Stany Zjednoczone, 60005
- GI Alliance
-
Gurnee, Illinois, Stany Zjednoczone, 60031
- GI Alliance
-
Northbrook, Illinois, Stany Zjednoczone, 60062
- Comprehensive Gastrointestinal Health
-
Rockford, Illinois, Stany Zjednoczone, 61107
- Rockford Gastroenterology Associates, Ltd.
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Indiana University
-
-
Iowa
-
Clive, Iowa, Stany Zjednoczone, 50325
- Iowa Digestive Disease Center
-
Iowa City, Iowa, Stany Zjednoczone, 52242-1009
- University of Iowa Hospitals & Clinics
-
-
Kansas
-
Kansas City, Kansas, Stany Zjednoczone, 66160
- University of Kansas Medical Center Research Institute, Inc.
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70809
- GI Alliance - Baton Rouge
-
Shreveport, Louisiana, Stany Zjednoczone, 71105
- Louisiana Research Center, LLC
-
-
Maryland
-
Columbia, Maryland, Stany Zjednoczone, 21045
- Gastro Center of Maryland
-
-
Massachusetts
-
Burlington, Massachusetts, Stany Zjednoczone, 01805
- Lahey Clinic Inc. - PARENT ACCOUNT
-
Worcester, Massachusetts, Stany Zjednoczone, 01655
- UMASS Memorial Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone, 87131-0001
- University of New Mexico
-
-
New York
-
New York, New York, Stany Zjednoczone, 10075-1850
- Lenox Hill Hospital
-
-
Ohio
-
Beavercreek, Ohio, Stany Zjednoczone, 45431
- Clinical Inquest Center Ltd
-
Dayton, Ohio, Stany Zjednoczone, 45415
- Dayton Gastroenterology, Inc
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97220-9442
- The Oregon Clinic, P.C.
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Stany Zjednoczone, 17011
- Susquehanna Research Group, LLC
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
- University of Pittsburgh Medical Center Health System
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15212
- Allegheny Center for Digestive Health
-
Uniontown, Pennsylvania, Stany Zjednoczone, 15401
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Summerville, South Carolina, Stany Zjednoczone, 29486
- Palmetto Primary Care Physician Division of Gastroenterology
-
-
South Dakota
-
Rapid City, South Dakota, Stany Zjednoczone, 57701
- Rapid City Medical Center, LLC
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37204
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78712
- The University of Texas at Austin
-
Houston, Texas, Stany Zjednoczone, 77030
- Baylor College of Medicine
-
Southlake, Texas, Stany Zjednoczone, 76092
- GI Alliance - Southlake
-
-
Utah
-
Ogden, Utah, Stany Zjednoczone, 84403
- Care Access Research Berkley
-
Salt Lake City, Utah, Stany Zjednoczone, 84132
- University of Utah
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- GCGA Physicians LLC
-
Lynchburg, Virginia, Stany Zjednoczone, 24502
- Gastroenterology Associates
-
-
Washington
-
Bellevue, Washington, Stany Zjednoczone, 98405
- GI Alliance
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
- Has agreed to use the CDPATH™ tool.
- Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.
Exclusion Criteria:
- Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
- Has had any non-CD-related abdominal surgery.
- Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
- Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: CDPATH™
Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis. |
Crohn's disease risk prediction tool.
Inne nazwy:
Three blood samples will be drawn. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Ramy czasowe: Baseline (Day 1)
|
The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years. |
Baseline (Day 1)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Ramy czasowe: Up to 36 months
|
Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification. |
Up to 36 months
|
|
Change From Baseline in Decisional Conflict Scale (DCS) Score
Ramy czasowe: Baseline, then every 6 months up to 36 months
|
DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict. |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Ramy czasowe: Baseline, then every 6 months up to 36 months
|
WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity). |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Ramy czasowe: Baseline, then every 6 months up to 36 months
|
PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health). |
Baseline, then every 6 months up to 36 months
|
|
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Ramy czasowe: Up to 36 months
|
Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool. |
Up to 36 months
|
|
Number of Participants with Clinical Outcomes
Ramy czasowe: Up to 36 months
|
Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported. |
Up to 36 months
|
|
Percentage of Participants with Healthcare Resource Utilization
Ramy czasowe: Up to 36 months
|
Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.). |
Up to 36 months
|
|
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Ramy czasowe: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability. |
First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Study Director, Takeda
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby jelit
- Choroby Układu Pokarmowego
- Choroby przewodu pokarmowego
- Nieżyt żołądka i jelit
- Choroby zapalne jelit
- Choroba Leśniowskiego-Crohna
- Techniki śledcze
- Prowadzenie okazów
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Nakłucia
- Procedury chirurgiczne, operacyjny
- Zbiór okazów krwi
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- Vedolizumab-4015
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Kryteria dostępu do udostępniania IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
- ICF
- CSR
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .